Evidence map›Paper›PMID 33016100›Full record

ArticleCirculation. Heart failure2020

Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.

Nasrien E Ibrahim, Ileana L Piña, Alexander Camacho, Devavrat Bapat, G Michael Felker, Alan S Maisel, Javed Butler, Margaret F Prescott, Cheryl A Abbas, Scott D Solomon and 2 more

2 registry-linked trialsOpen access · hybridAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02887183 phase4completednot on this map

A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.

TypeinterventionalSponsorNovartis PharmaceuticalsRan2016 to 2018Enrolled794ConditionsHeart FailureArmsLCZ696 (sacubitril/valsartan)
NCT06704633 phase4recruitingnot on this mapstarted 2026, after this paper: background citation

Health Status After Switching Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers to Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania: An Interventional Study

TypeinterventionalSponsorMartin RohacekRan2026 to 2028Enrolled298ConditionsHeart FailureArmsSacubitril / Valsartan Oral Tablet
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Social Inequalities in Non-ischemic Cardiomyopathies.Frontiers in cardiovascular medicine · 2022
    Review
  10. Reverse Cardiac Remodeling and ARNI Therapy.Current heart failure reports · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Nasrien E IbrahimCardiology Division, Massachusetts General Hospital, Boston (N.E.I., A.C., D.B., J.L.J.).
Ileana L PiñaWayne State University, Detroit, MI (I.L.P.).
Alexander CamachoCardiology Division, Massachusetts General Hospital, Boston (N.E.I., A.C., D.B., J.L.J.).
Devavrat BapatCardiology Division, Massachusetts General Hospital, Boston (N.E.I., A.C., D.B., J.L.J.).
G Michael FelkerCardiology Division, Duke University, Durham, NC (G.M.F.).
Alan S MaiselCardiology Division, University of California San Diego (A.S.M.).
Javed ButlerCardiology Division, University of Mississippi, Jackson (J.B.).
Margaret F PrescottNovartis Pharmaceuticals, East Hanover, NJ (M.F.P., C.A.A.).
Cheryl A AbbasNovartis Pharmaceuticals, East Hanover, NJ (M.F.P., C.A.A.).
Scott D SolomonHarvard Medical School, Boston, MA (N.E.I., S.D.S., J.L.J.).
James L JanuzziCardiology Division, Massachusetts General Hospital, Boston (N.E.I., A.C., D.B., J.L.J.).
Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE-HF) Study Investigators
Baim Institute for Clinical Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmong patients with heart failure and reduced ejection fraction (left ventricular (LV) ejection fraction ≤40%), sacubitril/valsartan (S/V) treatment is associated with improved health status and reverse cardiac remodeling. Data regarding racial and ethnic differences in response to S/V are lacking.

methodsThis was an analysis from the PROVE-HF study (Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure). Longitudinal changes in NT-proBNP (N-terminal pro-B-type natriuretic peptide), cardiac reverse remodeling, and health status scores were compared between groups using multivariate latent growth curve modeling.

resultsAmong the 782 patients included in this study, 22.7% were non-Hispanic Black (from here referred to as Black), 14.9% were Hispanic, and 62.4% were non-Hispanic White (from here referred to as White). At baseline, compared with White patients, Black and Hispanic patients had lower NT-proBNP (

conclusionsAmong Black, Hispanic, and White patients with heart failure and reduced ejection fraction, treatment with S/V was associated with similar reduction in NT-proBNP, improvement in health status, and reverse remodeling. More data regarding racial and ethnic responses to heart failure and reduced ejection fraction treatment are needed. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02887183.

Indexed as

Health Status DisparitiesAgedAminobutyratesBiomarkersBiphenyl CompoundsBlack or African AmericanCardiovascular AgentsDrug CombinationsFemaleHeart FailureHispanic or LatinoHumansLongitudinal StudiesMaleMiddle AgedNatriuretic Peptide, BrainAminobutyratesBiomarkersBiphenyl CompoundsCardiovascular AgentsDrug CombinationsNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)sacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanbiomarkerhealth statusheart failureventricular remodeling

Identifiers

PMID33016100
PMCPMC7769180
OpenAlexW3089907172

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.